- Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition - OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline - Sarepta's big bet on Arrowhead's siRNA assets yields early data

- Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition - OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline - Sarepta's big bet on Arrowhead's siRNA assets yields early data

- Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition - OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline - Sarepta's big bet on Arrowhead's siRNA assets yields early data

Share Episode#35 Mar 26th 2026: Merck's Terns Play

Sign up to save your podcasts

Episode#35 Mar 26th 2026: Merck's Terns Play

Episode#35 Mar 26th 2026: Merck's Terns Play